Biophytis (EPA:ALBPS) | WebDisclosure

PRESS RELEASE

published on 03/22/2024 at 07:01, 2 years ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie lors de l’ICFSR. L'étude SARA-31 vise à évaluer l'efficacité de RuvembriTM. La société recherche des partenaires pharmaceutiques pour le développer

Biophytis RuvembriTM Sarcopénie ICFSR Protocole De Phase 3
PRESS RELEASE

published on 03/22/2024 at 07:01, 2 years ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presented its phase 3 protocol for treating sarcopenia with Ruvembri at ICFSR conference, showing promising results in phase 2 study

Biophytis Ruvembri Phase 3 Protocol Sarcopenia Treatment ICFSR Conference
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 2 years ago

Biophytis a présenté son protocole de phase 3 dans le traitement de la sarcopénie
Biophy's présente son protocole de phase 3 pour traiter la sarcopénie lors de l'ICFSR. L'étude SARA-31 évaluera l'efficacité de RuvembriTM. Biophytis recherche des partenaires pour le développement

Biophytis RuvembriTM Sarcopénie Biophy's Protocole De Phase 3
REGULATED PRESS RELEASE

published on 03/22/2024 at 07:00, 2 years ago

Biophytis presented its phase 3 protocol in the treatment of sarcopenia
Biophytis presents phase 3 protocol for sarcopenia treatment at ICFSR conference, showcasing the potential of RuvembriTM. CEO Stanislas Veillet seeks partners for drug development and financing

Biophytis RuvembriTM Clinical-stage Biotechnology Phase 3 Protocol Sarcopenia Treatment
BRIEF

published on 03/18/2024 at 07:05, 2 years ago

Biophytis annonce sa prochaine Assemblée Générale Mixte pour le 02 avril 2024

Biophytis Assemblée Générale Mixte Société Biotechnologique Vote Des Actionnaires Médicaments Vieillissement
BRIEF

published on 03/18/2024 at 07:05, 2 years ago

Biophytis Announces Combined General Meeting for April 2024

Biophytis RuvembriTM Clinical-stage Biotechnology Combined General Meeting Age-related Diseases
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 2 years ago

Assemblée générale mixte du 02 avril 2024
Assemblée générale mixte de Biophytis SA prévue le 02 avril 2024 à Paris. Actionnaires invités à voter en amont. Informations sur le site internet de la Société

Assemblée Générale Mixte Biophytis SA Vote Actionnaires Développement Médicaments Maladies Liées Au Vieillissement
REGULATED PRESS RELEASE

published on 03/18/2024 at 07:00, 2 years ago

Combined General Meeting of April 2, 2024
Biophytis SA will hold its Combined General Meeting (CGM) on April 2, 2024 at Sorbonne Université, Paris. Shareholders can vote in advance. The company specializes in developing therapies for age-related diseases

Therapeutics Combined General Meeting Biophytis SA Age-related Diseases CGM
BRIEF

published on 03/15/2024 at 23:05, 2 years ago

Biophytis met en œuvre le regroupement de ses actions pour réduire la volatilité

Marché Financier Biophytis Biotechnologie Regroupement D'actions Volatilité Du Titre
BRIEF

published on 03/15/2024 at 23:05, 2 years ago

Biophytis Announces Reverse Stock Split on Euronext Growth

Biophytis Biotechnology Shareholder Value Reverse Stock Split Euronext Growth

Published on 03/24/2026 at 08:01, 1 hour 29 minutes ago

Star Copper Confirms Copper Creek Mineralization
Published on 03/24/2026 at 07:00, 2 hours 30 minutes ago

Panther Minerals Earns In Under Rubidium Ridge Project Option
Published on 03/24/2026 at 07:00, 2 hours 30 minutes ago

Panther Completes Acquisition of Rubidium Ridge Project
Published on 03/24/2026 at 00:55, 8 hours 35 minutes ago

BTU Closes Oversubscribed Financing
Published on 03/23/2026 at 22:40, 10 hours 50 minutes ago

Troubadour Announces Withdrawal of Non-Brokered Private Placements

View all ACCESSWIRE

Published on 03/24/2026 at 09:21, 9 minutes ago

More than 3,000 GHG credits successfully processed: Customers benefit from the services of the Allane Mobility Group
Published on 03/24/2026 at 09:15, 15 minutes ago

Julius Baer Group Ltd. to redeem Perpetual Tier 1 Subordinated Bonds issued 8 October 2020 on first call date
Published on 03/24/2026 at 09:10, 20 minutes ago

DN Group AG acquires a stake in WINDWISE / Further expansion of the portfolio
Published on 03/24/2026 at 09:05, 25 minutes ago

Nagarro announces preliminary numbers for FY 2025, guidance for FY 2026, and conclusion of independent investigation
Published on 03/24/2026 at 09:05, 25 minutes ago

MSI Highlights Cloud, AI, and Enterprise Server Platforms at CloudFest 2026

View all EQS

Published on 03/24/2026 at 07:45, 1 hour 45 minutes ago

François Jackow’s appointment as a Board member will be submitted to the Annual General Meeting on May 7, 2026
Published on 03/24/2026 at 07:45, 1 hour 45 minutes ago

La nomination de François Jackow en tant que membre du Conseil d’administration sera soumise à l’Assemblée générale du 7 mai 2026
Published on 03/24/2026 at 07:30, 2 hours ago

Gimv secures new EUR 400 million revolving credit facility to support accelerated growth ambitions
Published on 03/24/2026 at 07:30, 2 hours ago

Gimv verzekert zich van een nieuwe Revolving Credit Facility van EUR 400 miljoen ter ondersteuning van de versnelde groeiambities
Published on 03/23/2026 at 19:08, 14 hours 22 minutes ago

Reporting on share buyback transactions carried out between March 16 and March 20, 2026

View all LES ECHOS COMFI WIRE

News